Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | DDO | Q99489 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | KIF11 | P52732 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29713806 | 1.00 | DAO (0.56) | DAODDOCYP1A2GAARXFP1 | |
| Formaldehyde SCHEMBL28245545 | 0.94 | DAO (0.56) | DAODDOCYP1A2GAARXFP1 | |
| SCHEMBL15045461 | 0.84 | NQO2 (0.51) | DAODDOCYP1A2GAARXFP1 | |
| SCHEMBL4071480 | 0.80 | DAO (0.55) | DAODDOCYP1A2GAARXFP1 | |
| SCHEMBL30939503 | 0.80 | DAO (0.55) | DAODDOCYP1A2GAARXFP1 | |
| SCHEMBL15829262 | 0.79 | DAO (0.50) | DAODDOCYP1A2GAARXFP1 | |
| SCHEMBL19373476 | 0.78 | DAO (0.62) | DAODDOCYP1A2GAAKIF11 | |
| SCHEMBL20461945 | 0.78 | GAA (0.50) | DAODDOCYP1A2GAARXFP1 | |
| SCHEMBL1353956 | 0.78 | PARP1 (0.59) | CYP1A2GAARXFP1KIF11CYP2A6 | |
| SCHEMBL933745 | 0.78 | GAA (0.50) | DAODDOCYP1A2GAARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113045724-B | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-113045724-A | Phosphonic acid water reducing agent containing indole skeleton structure, and preparation method and application thereof | 江苏苏博特新材料股份有限公司 | 2021-06-29 | — | — | CN | claimed |
| US-20250263760-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-08-21 | — | — | US | disclosed |
| US-12319946-B2 | Methods for producing modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-06-03 | — | — | US | disclosed |
| EP-3928836-B1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-18 | — | — | EP | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240229090-A1 | MODIFIED BACTERIA FOR PRODUCTION OF NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-07-11 | — | — | US | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| US-11879144-B2 | Modified bacteria for production of nitroaromatics | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| WO-2007106503-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056280-A1 | INDOLE COMPOUNDS HAVING C4-ACIDIC SUBSTITUENTS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056281-A2 | MULTIVALENT INDOLE COMPOUNDS AND USE THEREOF AS PHOSPHOLIPASE-A2 INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2005051901-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-06-09 | — | — | WO | disclosed |
| EP-0409949-B1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | ICI PLC (GB) | 1994-05-18 | — | — | EP | disclosed |
| US-5185452-A | Antidiabetic agents; aldose reductase inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-02-09 | — | — | US | disclosed |
| EP-0409949-A1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | ICI PLC (GB) | 1991-01-30 | — | — | EP | disclosed |
| WO-1990008763-A1 | ARYLSULPHONYL-NITROMETHANES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | DAO 3755/4885DDO 4557/4885CYP1A2 104/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | DAO 878/4885DDO 807/4885CYP1A2 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.